TLR7 and neoplasm: Delivery of TLR7/8 moieties by Smith et al. in PEG−PLA nanoparticles led to slower tumour growth, extended survival and decreased systemic toxicity in comparison to free TLR7/8a when used along with anti-PD-L1 checkpoint blockade [28].